Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential therapeutic tool for biliary and pancreatic diseases. Frail and elderly patients, especially those aged ≥ 90 years are generally considered a higher-risk population for ERCP-related complications.
To investigate outcomes of ERCP in the Non-agenarian population (≥ 90 years) concerning Frailty.
This is a cohort study using the 2018-2020 National Readmission Database. Patients aged ≥ 90 were identified who underwent ERCP, using the international classification of diseases-10 code with clinical modification. Johns Hopkins's adjusted clinical groups frailty indicator was used to classify patients as frail and non-frail. The primary outcome was mortality, and the secondary outcomes were morbidity and the 30 d readmission rate related to ERCP. We used univariate and multivariate regression models for analysis.
A total of 9448 patients were admitted for any indications of ERCP. Frail and non-frail patients were 3445 (36.46%) and 6003 (63.53%) respectively. Indications for ERCP were Choledocholithiasis (74.84%), Biliary pancreatitis (9.19%), Pancreatico-biliary cancer (7.6%), Biliary stricture (4.84%), and Cholangitis (1.51%). Mortality rates were higher in frail group [adjusted odds ratio (aOR) = 1.68,
= 0.02]. The Intra-procedural complications were insignificant between the two groups which included bleeding (aOR = 0.72,
= 0.67), accidental punctures/lacerations (aOR = 0.77,
= 0.5), and mechanical ventilation rates (aOR = 1.19,
= 0.6). Post-ERCP complication rate was similar for bleeding (aOR = 0.72,
= 0.41) and post-ERCP pancreatitis (aOR = 1.4,
= 0.44). Frail patients had a longer length of stay (6.7 d
5.5 d) and higher mean total charges of hospitalization ($78807
$71392) compared to controls (
< 0.001). The 30 d all-cause readmission rates between frail and non-frail patients were similar (
= 0.96).
There was a significantly higher mortality risk and healthcare burden amongst nonagenarian frail patients undergoing ERCP compared to non-frail. Larger studies are warranted to investigate and mitigate modifiable risk factors.